-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nektar Therapeutics (NASDAQ:NKTR) Director Myriam Curet Sells 4,198 Shares of Stock
Nektar Therapeutics (NASDAQ:NKTR) Director Myriam Curet Sells 4,198 Shares of Stock
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) Director Myriam Curet sold 4,198 shares of the stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $3.16, for a total value of $13,265.68. Following the completion of the sale, the director now directly owns 31,777 shares of the company's stock, valued at approximately $100,415.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Nektar Therapeutics Price Performance
NASDAQ NKTR opened at $3.08 on Tuesday. The business has a 50 day simple moving average of $4.10 and a 200 day simple moving average of $4.26. Nektar Therapeutics has a one year low of $3.02 and a one year high of $19.37. The stock has a market capitalization of $577.21 million, a P/E ratio of -1.09 and a beta of 1.16.
Get Nektar Therapeutics alerts:Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.16. Nektar Therapeutics had a negative return on equity of 82.40% and a negative net margin of 544.77%. The business had revenue of $21.59 million during the quarter, compared to analysts' expectations of $22.75 million. During the same quarter last year, the firm posted ($0.69) earnings per share. The firm's revenue was down 23.8% on a year-over-year basis. Equities analysts expect that Nektar Therapeutics will post -2.14 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on NKTR. JPMorgan Chase & Co. cut Nektar Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Monday, August 8th. StockNews.com raised Nektar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, August 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $13.17.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Calton & Associates Inc. bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Vantage Consulting Group Inc bought a new position in Nektar Therapeutics in the second quarter worth approximately $41,000. Arete Wealth Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $59,000. Finally, Halbert Hargrove Global Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $61,000. Institutional investors own 96.99% of the company's stock.
Nektar Therapeutics Company Profile
(Get Rating)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
See Also
- Get a free copy of the StockNews.com research report on Nektar Therapeutics (NKTR)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- Is the Market Overreacting with Shopify Stock?
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) Director Myriam Curet sold 4,198 shares of the stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $3.16, for a total value of $13,265.68. Following the completion of the sale, the director now directly owns 31,777 shares of the company's stock, valued at approximately $100,415.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
在一笔日期为9月23日(星期五)的交易中,董事Myriam Curet出售了4,198股该股。这些股票的平均价格为3.16美元,总价值为13,265.68美元。出售完成后,董事现在直接拥有该公司31,777股股票,价值约100,415.32美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在美国证券交易委员会网站.
Nektar Therapeutics Price Performance
Nektar治疗公司的价格表现
NASDAQ NKTR opened at $3.08 on Tuesday. The business has a 50 day simple moving average of $4.10 and a 200 day simple moving average of $4.26. Nektar Therapeutics has a one year low of $3.02 and a one year high of $19.37. The stock has a market capitalization of $577.21 million, a P/E ratio of -1.09 and a beta of 1.16.
纳斯达克nktr周二开盘报3.08美元。该业务的50日简单移动均线切入位在4.10美元,200日简单移动均线切入位在4.26美元。Nektar治疗公司的一年低点为3.02美元,一年高位为19.37美元。该股市值为5.7721亿美元,市盈率为-1.09,贝塔系数为1.16。
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.16. Nektar Therapeutics had a negative return on equity of 82.40% and a negative net margin of 544.77%. The business had revenue of $21.59 million during the quarter, compared to analysts' expectations of $22.75 million. During the same quarter last year, the firm posted ($0.69) earnings per share. The firm's revenue was down 23.8% on a year-over-year basis. Equities analysts expect that Nektar Therapeutics will post -2.14 earnings per share for the current year.
Nektar治疗公司(纳斯达克代码:NKTR-GET评级)最近一次公布收益结果是在8月4日星期四。这家生物制药公司公布了本季度每股收益(0.85美元),比普遍预期的(1.01美元)高出0.16美元。Nektar治疗公司的净资产回报率为负82.40%,净利润率为负544.77%。该业务当季营收为2,159万美元,高于分析师预期的2,275万美元。去年同期,该公司公布的每股收益为0.69美元。该公司的收入同比下降了23.8%。股票分析师预计,Nektar治疗公司本年度的每股收益将达到2.14美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Calton & Associates Inc. bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Vantage Consulting Group Inc bought a new position in Nektar Therapeutics in the second quarter worth approximately $41,000. Arete Wealth Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $59,000. Finally, Halbert Hargrove Global Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $61,000. Institutional investors own 96.99% of the company's stock.
机构投资者和对冲基金最近增持或减持了该公司的股份。Verition Fund Management LLC在第一季度购买了Nektar治疗公司的一个新头寸,价值约55,000美元。Calton&Associates Inc.在第一季度购买了Nektar治疗公司的一个新头寸,价值约55,000美元。Vantage咨询集团在第二季度购买了Nektar治疗公司的一个新头寸,价值约41,000美元。Arete Wealth Advisors LLC在第一季度购买了Nektar治疗公司的一个新头寸,价值约59,000美元。最后,Halbert Hargrove Global Advisors LLC在第一季度购买了Nektar治疗公司的一个新头寸,价值约61,000美元。机构投资者持有该公司96.99%的股票。
Nektar Therapeutics Company Profile
Nektar治疗公司简介
(Get Rating)
(获取评级)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
Nektar治疗公司是一家生物制药公司,专注于在美国和国际上未得到满足的医疗需求领域发现和开发药物。该公司的产品包括治疗转移性黑色素瘤、肾细胞癌、肌肉浸润性膀胱癌、头颈部鳞状细胞癌和佐剂性黑色素瘤的CD122偏好的白介素2途径激动剂Bempegaldesil;治疗肾细胞癌、非小细胞肺癌和尿路上皮癌的2期临床试验;治疗头颈部鳞状细胞癌的1/2A期临床试验;治疗实体肿瘤的1/2期临床试验;以及治疗新冠肺炎的1B期临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Nektar Therapeutics (NKTR)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- Is the Market Overreacting with Shopify Stock?
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
- 免费获取StockNews.com关于Nektar治疗公司(NKTR)的研究报告
- MarketBeat Podcast,3只股票关注纽蒙特矿业、沃尔玛、AMC
- Mo Money:奥驰亚集团股价为何上涨
- 市场是否对Shopify Stock反应过度?
- 美联储加息:3只股票关注纽蒙特矿业、沃尔玛、AMC
- 三只可能在第四季度表现优异的消费类股
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Nektar治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nektar治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧